Bonerge Lifescience Launches Clinical Study on EquoYouth® S-Equol for Menopause Symptom Relief

Bonerge Lifescience Launches Clinical Study on EquoYouth® S-Equol for Menopause Symptom Relief

Open-label trial will evaluate a 12-week, 10 mg daily regimen of the company's high-purity S-equol ingredient in women with moderate menopausal symptoms.

Bonerge Lifescience announced a new clinical study evaluating EquoYouth®, its branded S-equol ingredient, for its potential to ease menopausal symptoms and support women through the menopausal transition — without the use of hormones.

Study Design at a Glance

• Design: Open-label, single-arm clinical trial
• Participants: Women aged 45–60 with moderate menopausal symptoms
• Regimen: 10 mg S-equol daily for 12 weeks
• Measures: Symptom severity, sleep quality, emotional well-being, cognitive function, quality of life, and safety parameters

Unlike most published S-equol research, which has centered on hot flash frequency, this design also incorporates validated sleep, mood and cognitive assessments alongside breast and endometrial ultrasound monitoring — addressing evidence gaps that remain open in the existing literature.

This exploratory study marks the first stage of Bonerge's broader clinical research program for EquoYouth®. Once complete, the company plans to move into a randomized, double-blind, placebo-controlled trial to further confirm the ingredient's efficacy and safety profile.

Why S-Equol Matters for Menopause Support

S-equol is a metabolite the body produces when gut bacteria convert soy isoflavones — but not every woman's microbiome can make that conversion. Research suggests only about a third to half of women in Western populations naturally produce equol, leaving a large group of "non-producers" without access to its benefits through diet alone. Direct S-equol supplementation gives these women a consistent way to access the compound, regardless of their gut microbiota composition.

Once in the body, S-equol binds selectively to estrogen receptor beta (ERβ), allowing it to support hormonal balance without acting like a hormone itself — a distinction drawing growing interest as women look for non-hormonal options for menopause support.

What Earlier Research Shows

Prior published studies on 10 mg/day S-equol supplementation have pointed to improvements in hot flashes, sleep quality, mood, and muscle discomfort, with the most pronounced effects seen among equol non-producers — the group Bonerge's new study is designed to reach.

Backed by Purity and Compliance Credentials

EquoYouth® S-Equol is manufactured through a proprietary fermentation process that yields more than 99% purity by HPLC and is structurally identical to the S-equol naturally produced in the human gut. It is the first high-purity S-equol ingredient to achieve Self-Affirmed GRAS (SA-GRAS) status, and it carries FSSC 22000, Kosher, and Halal certifications.

Executive Comment

"Clinical validation is core to Bonerge's innovation strategy," said Allen,CEO at Bonerge Lifescience. "Through EquoYouth®, we're building a stronger evidence base for high-quality S-equol and giving global brands an ingredient they can trust — backed by rigorous, ongoing research."

About Bonerge Lifescience

Bonerge Lifescience is a science-driven ingredient innovator building the future of health — beyond raw ingredients. The company develops clinically supported, next-generation solutions across healthy aging, women's health, sleep, and metabolic wellness, backed by proprietary technology and rigorous research. Learn more at www.bonerge.com .

Cecilia Yang
sales@bonerge.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260727525044/en/